1 / 16

Genetic screening

Genetic screening. Genetic screening. Curriculum statement 6 Genetics in primary care “Demonstrate an awareness of antenatal and other screening programmes for genetic conditions” Antenatal screening programme Newborn screening programme General screening. Antenatal/newborn screening.

hammett-maxwell
Download Presentation

Genetic screening

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Genetic screening

  2. Genetic screening • Curriculum statement 6 Genetics in primary care • “Demonstrate an awareness of antenatal and other screening programmes for genetic conditions” • Antenatal screening programme • Newborn screening programme • General screening

  3. Antenatal/newborn screening • NHS Sickle cell and Thalassaemia programme • Pregnant women • New born babies • NHS newborn blood spot screening programme • Phenylketonuria (PKU) • Congenital hypothyroidism (CHT) • Sickle cell disease (SCD) • Cystic fibrosis (CF) • medium-chain acyl-CoA dehydrogenase deficiency (MCADD) • Foetal anomaly screening programme • Includes screening for Down’s syndrome

  4. NHS Sickle cell and Thalassaemia programme • set up 2001 • first “linked” programme – i.e. mother’s blood results linked to baby’s results • covers both antenatal and new born screening • all pregnant women should be offered testing, ideally before 10 weeks • pregnant women from “high” prevalence trusts should be automatically screened, those from “low” prevalence trusts screened using Family Origin Questionnaire (FOQ)

  5. Haemoglobinopathies most common within communities from tropics/sub-tropics • Currently 700,000 carriers (1.2% of the population) and 10% of the ethnic population • Sickle cell • 240,000 carriers / 12,500 affected (currently) • 2008/9: 670,00 newborn samples screened – 360 screen +ive with disease (1/2000 births), 9600 identified as carriers • Thalassaemia • 214,000 carriers / 700 affected (currently)

  6. Family origin questionnaire • For pregnant women living in an area with “low risk” (foetal prevalence < 1.5/10,000 pregnancies) used to identify women at risk of being a carrier or baby with Haemoglobin disorder • Ascertain family origins of mother and father for at least 2 generations • For women living in “high risk” areas helps lab staff interpret results

  7. The future… • Does it make a difference? • Not enough evidence from the UK • USA: reduction in mortality in early infancy, earlier interventions • Preconception screening? • Saudi Arabia: increase in number of at-risk couples who cancel marriage proposals • Lazio, Italy: universal screening secondary schools led to reduction in affected births • What do patients understand? • Poor understanding of carrier status by patients • Lack of understanding by professionals

  8. Link to NHS Sickle Cell and Thalassaemia Screening programme leaflets • http://sct.screening.nhs.uk/leaflets

  9. NHS newborn blood spot screening programme • Established 1969 for PKU and 1981 for CHT • Screens 600,000 newborns every year • > 99% babies screened, taken day 5-8 • Covers: • Phenylketonuria (PKU) • Congenital hypothyroidism (CHT) • Sickle cell disease (SCD) • Cystic fibrosis (CF) • medium-chain acyl-CoA dehydrogenase deficiency (MCADD)

  10. Phenylketonuria (PKU) • Autosomal recessive condition • Affects 1/10,000 births, 66 cases diagnosed each year • Twice as common in Ireland • Abnormally high levels of Phenylalanine due to reduction in phenylalanine hydroxylase • “Classical” PKU = severe mental disability and seizures if untreated • “Benign” PKU = mild/moderate mental disability if untreated • Treatment = special diet • Aim to diagnose and start treatment before 21 days of age

  11. Cystic Fibrosis (CF) • Introduced 1980 in England but not universal until 2001 • Autosomal recessive • Large number of gene mutations with range of different clinical phenotypes • Blood spot tests Immunoreactive Trypsinogen (IRT) • If raised, combination of DNA mutation analysis and 2nd blood spot IRT performed • Then confirmed with sweat test (if +ive or equivocal)

  12. Medium-chain acyl-CoA dehydrogenase deficiency (MCADD) • Testing started 2007, universal in England from 2009 • Autosomal recessive, deficiency of Medium chain Acyl-CoA Dehydrogenase (needed to break down medium chain fatty acids) • Complications arise during times of “stress” i.e. cannot break down fat stores so become hypoglycaemic leading to seizures/brain damage/death • Generally no symptoms at birth, 1/3rd remain asymptommatic • Blood spot tests for raised Octanoylcarnitine • Treatment = strict feeding regime

  13. Down’s screening programme • Trisomy 21 – 3 instead of 2 chromosomes • Risk increases with maternal age (1/1500 aged 20 yrs, 1/900 aged 30 yrs and 1/100 aged 40 yrs) • Offered to all pregnant women • Generates a risk only (i.e. high or low risk) • If high (more than or equal to 1/150) diagnostic procedures offered (Amniocentesis/Chorionic Villous Sampling)

  14. Down’s screening programme • First trimester = Combined Screening test • Offered from 10+0 to 14+1 weeks • Bloods: bHCG and PAPP-A (Pregnancy associated plasma protein A) • USS:Foetal crown-rump length and Nuchal translucency (significant if more than or equal to 3.5mm) • Above results + Maternal age used to calculate risk • Complies with standard of > 90% detection rate and < 2% screen positive rate

  15. Down’s screening programme • Second trimester = Quadruple Screening test • Offered from 14+2 – 20+0 • Bloods: bHCG, aFP, Oestriol and Inhibin A • Performance as a screening test less than that of Combined (meets detection rate > 75% and screen positive rate of < 3%)

  16. Hopefully… • Better understanding of genetic screening in antenatal and newborn period • Increased confidence when discussing with patients

More Related